Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Feb 5, 2024

31100_dirs_2024-02-05_9f7549cf-30c4-4ee3-a341-e4cfde9a56fb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-02-01

Reporting Person: Wassil Jim (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-01 Common Stock M 3000 $2.42 Acquired 178935 Direct
2024-02-01 Common Stock S 527 $72.177 Disposed 178408 Direct
2024-02-01 Common Stock S 1056 $73.345 Disposed 177352 Direct
2024-02-01 Common Stock S 467 $74.136 Disposed 176885 Direct
2024-02-01 Common Stock S 950 $75.279 Disposed 175935 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-01 Stock Option (right to buy) $2.42 M 3000 Disposed 2029-12-16 Common Stock (3000) Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $72.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.71 to $73.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.77 to $74.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.80 to $75.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.